奥精医疗：胶原蛋白止血海绵获批，产品多元化再迈步

Core Viewpoint - Aojing Medical (688613.SH) announced that its subsidiary, Beijing Aojing Medical Device Co., Ltd., has received approval for its absorbable collagen hemostatic sponge, marking a significant advancement in its product offerings and competitive position in the medical device market [1][2]. Group 1 - The collagen sponge is approved for use in various surgical procedures (excluding ophthalmology, urology, and neurosurgery) to control bleeding when traditional methods are ineffective, applicable in diverse medical settings [1]. - Collagen not only promotes cell growth but also maintains cell division functions, making it widely used in wound dressings and aesthetic medicine [1]. - The approval of the medical device registration certificate is expected to enhance the company's product matrix and overall competitiveness [1]. Group 2 - The company is actively diversifying its product line through independent research and development, as well as mergers and acquisitions, with over ten projects in development, including collagen dressings and artificial skin [2]. - In the first half of the year, the company acquired the German implant brand HumanTech Dental, marking its entry into the dental implant sector and extending its reach from serious medical to consumer healthcare [2]. - Following the certification of the collagen sponge, the company plans to apply for production licenses, which is anticipated to create new revenue growth opportunities [2].